Citation Impact
Citing Papers
Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro
2006 StandoutNobel
Neutralizing antibody response during acute and chronic hepatitis C virus infection
2004 StandoutNobel
Plasmacytoid dendritic cells initiate a complex chemokine and cytokine network and are a viable drug target in chronic HCV patients
2007 StandoutNobel
Evidence for a functional RNA element in the hepatitis C virus core gene
2007 StandoutNobel
Mouse models of acute and chronic hepacivirus infection
2017 StandoutScienceNobel
Proteomics of HCV virions reveals an essential role for the nucleoporin Nup98 in virus morphogenesis
2016 StandoutNobel
Faldaprevir (Bi 201335), Deleobuvir (Bi 207127) and Ribavirin Oral Therapy for Treatment-Naive HCV Genotype 1: Sound-C1 Final Results
2013
Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection
2016
Emerging therapies for the treatment of hepatitis C
2013 StandoutNobel
The Spring α-Helix Coordinates Multiple Modes of HCV (Hepatitis C Virus) NS3 Helicase Action
2016 StandoutNobel
Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial
2013
Phage-assisted evolution of an adenine base editor with improved Cas domain compatibility and activity
2020 StandoutNobel
SEC14L2 enables pan-genotype HCV replication in cell culture
2015 StandoutNatureNobel
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus
2009 StandoutNature
Animal Models for the Study of Hepatitis C Virus Infection and Related Liver Disease
2012
Treatment triumphs
2014 StandoutNatureNobel
Exploratory Study of Oral Combination Antiviral Therapy for Hepatitis C
2013
DNA recognition by an RNA-guided bacterial Argonaute
2017 StandoutNobel
Hepatitis C virus induces interferon-λ and interferon-stimulated genes in primary liver cultures
2010 StandoutNobel
Expression of paramyxovirus V proteins promotes replication and spread of hepatitis C virus in cultures of primary human fetal liver cells
2010 StandoutNobel
The importance of resistance to direct antiviral drugs in HCV infection in clinical practice
2015
Unconventional miR-122 binding stabilizes the HCV genome by forming a trimolecular RNA structure
2013 StandoutNobel
Whole Genome Pyrosequencing of Rare Hepatitis C Virus Genotypes Enhances Subtype Classification and Identification of Naturally Occurring Drug Resistance Variants
2012
The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection
2013
Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C
2016
Lethal Mutagenesis of Hepatitis C Virus Induced by Favipiravir
2016 StandoutNobel
Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C
2013
The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C
2011
The role of resistance in HCV treatment
2012
Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial
2015
Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b–infected null responders
2011
Perspectives and challenges of interferon-free therapy for chronic hepatitis C
2012
Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
2014
Metazoan MicroRNAs
2018 Standout
miRNA–target chimeras reveal miRNA 3′-end pairing as a major determinant of Argonaute target specificity
2015 StandoutNobel
Antiviral strategies in hepatitis C virus infection
2012
New Hepatitis C Therapies: The Toolbox, Strategies, and Challenges
2014
Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: Updated criteria and genotype assignment web resource
2013 StandoutNobel
Sofosbuvir Inhibits Hepatitis E Virus Replication In Vitro and Results in an Additive Effect When Combined With Ribavirin
2015 StandoutNobel
The ins and outs of hepatitis C virus entry and assembly
2013 StandoutNobel
Efficacy of the Protease Inhibitor BI 201335, Polymerase Inhibitor BI 207127, and Ribavirin in Patients With Chronic HCV Infection
2011
Argonaute CLIP Defines a Deregulated miR-122-Bound Transcriptome that Correlates with Patient Survival in Human Liver Cancer
2017 StandoutNobel
A diverse range of gene products are effectors of the type I interferon antiviral response
2011 StandoutNatureNobel
Hepatitis C Virus-Specific Directly Acting Antiviral Drugs
2013
Global control of hepatitis C: where challenge meets opportunity
2013
Dancing with chemical formulae of antivirals: A panoramic view (Part 2)
2013
The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
2014 Standout
Understanding the hepatitis C virus life cycle paves the way for highly effective therapies
2013 StandoutNobel
Novel therapies for hepatitis C — one pill fits all?
2013
Sofosbuvir and Daclatasvir Combination Therapy in a Liver Transplant Recipient With Severe Recurrent Cholestatic Hepatitis C
2013
Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
2014
What Are the Promising New Therapies in the Field of Chronic Hepatitis C After the First-Generation Direct-Acting Antivirals?
2012
A system for the continuous directed evolution of proteases rapidly reveals drug-resistance mutations
2014
25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end
2013
Tumor Necrosis Factor Inhibits Spread of Hepatitis C Virus Among Liver Cells, Independent From Interferons
2017 StandoutNobel
Treatment of HCV Infection by Targeting MicroRNA
2013 Standout
Treatment of Chronic Hepatitis C: Current and Future
2013
Current race in the development of DAAs (direct-acting antivirals) against HCV
2014
Hepatitis C Virus RNA Functionally Sequesters miR-122
2015 StandoutNobel
Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles
2003 StandoutNobel
Hepatitis C virus infects rhesus macaque hepatocytes and simianized mice
2015 StandoutNobel
Ultrastructural analysis of hepatitis C virus particles
2013 StandoutNobel
Robust full-length hepatitis C virus genotype 2a and 2b infectious cultures using mutations identified by a systematic approach applicable to patient strains
2012
Characterization of nonprimate hepacivirus and construction of a functional molecular clone
2015 StandoutNobel
Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus
2012 StandoutNobel
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Chromone: A Valid Scaffold in Medicinal Chemistry
2014 Standout
A bacterial Argonaute with noncanonical guide RNA specificity
2016 StandoutNobel
Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life
2013
Hepatitis C Virus NS3 Inhibitors: Current and Future Perspectives
2013
Hepatitis C Virus p7 and NS2 Proteins Are Essential for Production of Infectious Virus
2007 StandoutNobel
Response of Hepatitis C Virus to Long-Term Passage in the Presence of Alpha Interferon: Multiple Mutations and a Common Phenotype
2013 StandoutNobel
Cellular cofactors affecting hepatitis C virus infection and replication
2007 StandoutNobel
EASL Recommendations on Treatment of Hepatitis C 2018
2018 Standout
Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs
2002 StandoutNobel
Viral persistence, liver disease, and host response in a hepatitis C–like virus rat model
2017 StandoutNobel
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
Time- and Temperature-Dependent Activation of Hepatitis C Virus for Low-pH-Triggered Entry
2006 StandoutNobel
Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants with in vitro resistance to SR-BI-targeting agents
2014 StandoutNobel
Activation of naïve B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders
2005 StandoutNobel
Discovery of Daclatasvir, a Pan-Genotypic Hepatitis C Virus NS5A Replication Complex Inhibitor with Potent Clinical Effect
2014
Hepatitis C Virus Glycoproteins Interact with DC-SIGN and DC-SIGNR
2003 StandoutNobel
New therapeutic strategies in HCV: second‐generation protease inhibitors
2013
Novel Therapies for Hepatitis C: Insights from the Structure of the Virus
2011
Persistence of Resistant Variants in Hepatitis C Virus-Infected Patients Treated with the NS5A Replication Complex Inhibitor Daclatasvir
2013
Importance of HCV genotype 1 subtypes for drug resistance and response to therapy
2014
Works of Timothy Eley being referenced
Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders
2013
Resistance Analysis of Hepatitis C Virus Genotype 1 Prior Treatment Null Responders Receiving Daclatasvir And Asunaprevir
2013
Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1
2012
Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options
2012
The Pharmacokinetics of Daclatasvir and Asunaprevir Administered in Combination in Studies in Healthy Subjects and Patients Infected with Hepatitis C Virus
2014
Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C
2014
1415 CONFIRMATION THAT QUADRUPLE THERAPY WITH DACLATASVIR (NS5A INHIBITOR), ASUNAPREVIR (NS3 INHIBITOR) AND PEGINTERFERON/RIBAVIRIN RESULTS IN HIGH RATE OF SVR4 IN HCV GENOTYPE 1 NULL RESPONDERS
2012
1420 ASUNAPREVIR WITH PEGINTERFERON-ALFA AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS WITH GENOTYPE-1 OR -4 CHRONIC HEPATITIS C: SVR24 RESULTS FROM A RANDOMIZED PHASE 2B STUDY (AI447016)
2013
1356 QUADRUPLE THERAPY WITH BMS-790052, BMS-650032 AND PEG-IFN/RBV FOR 24 WEEKS RESULTS IN 100% SVR12 IN HCV GENOTYPE 1 NULL RESPONDERS
2011
1422 POTENT VIRAL SUPPRESSION WITH ALL-ORAL COMBINATION OF DACLATASVIR (NS5A INHIBITOR) AND GS-7977 (NS5B INHIBITOR), +/− RIBAVIRIN, IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GT1, 2, OR 3
2012